A recent study also discovered that increased expression of immune response-related genes, BTN3A2, CD2, and TRBC1 was correlated with favorable prognosis of HR−/HER2+ breast cancer, indicating the importance of immune response-related genes in predicting the treatment outcome for this subtype [30]. The gene discussed is CD2; the disease is breast carcinoma.